Post by
smallcapcanada on Apr 20, 2018 1:29pm
MPX and Their Future in Cannabis Derivatives
MPX has a pretty clear understanding of what they want their future to look like- producing cannabis derivatives for the domestic and export markets. They took a pretty big step toward that goal when they announced the acquisition of Canveda, including their fully built-out facility that is ready to commence its first production run and is capable of producing approximately 1,000-1,200 kilograms of high quality cannabis flower annually.
Having already established a presence in Arizona, the Canveda acquisition will finally put MPX on home soil and perhaps more importantly, establish them as a real player in the medicinal MJ market. That is significant when you consider the medicinal MJ market is expected to hit $55.8 billion by 2025.
MPX has already said they plan to replicate their vertical integration approach for their future operations and they are currently exploring partnerships with potential operators of dispensaries in Western Canada.
Not to be missed, MPX also has said they intend to expand their existing partner relationships into the Canadian market, including the production and marketing arrangement they have with leading Israeli pharmaceutical company, Panaxia.
SmallCapCanada (.com)
Comment by
Rolli57 on Apr 25, 2018 1:10pm
Here is a great validation of their strategy from CNBC-